The James Buchanan Brady Urological Institute
 
 
 
  PROSTATE CANCER          Appointments: 410-550-6100

Our Surgeons

Mohamad E. Allaf, M.D.

Trinity J. Bivalacqua, M.D, Ph.D 

Arthur L. Burnett, II, M. D.
 

H. Ballentine Carter, M.D.


Misop Han, M.D.

Jacek L. Mostwin, M.D., D.Phil,(Oxon.)


Alan Partin, M.D., Ph.D

Christian Pavlovich, M.D.

Edward M. Schaeffer, M.D., Ph.D. 

Patrick C. Walsh, M.D.


SPECIAL PROSTATE ALERT: PSA CONTROVERSY

The recent contradictory studies of more than 240,000 men published in the New England Journal of Medicine (NEJM) about the effectiveness of using the prostate specific antigen (PSA) test for reducing death from prostate cancer left many men and physicians confused, upset, disappointed, and wondering what they should now do. One study reported that PSA saves lives, while the other noted no benefit whatsoever.

To help our readers with this confusing data, we asked H. Ballentine Carter, M.D., Director of Adult Urology, and Patrick C. Walsh, M.D., University Distinguished Service Professor of Urology , to provides their thoughts.


Dr. Carter Response

Dr. Walsh Response

 





© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287